Liran Belenzon

CEO & Co-Founder, BenchSci

Liran Belenzon is the Co-founder and CEO of BenchSci, a platform focused on improving drug discovery through artificial intelligence. Founded in 2015, BenchSci’s ASCEND platform aims to address the
challenges of productivity in the pharmaceutical industry. The company has rapidly expanded from its original four co-founders to a team of 250 employees, raising more than $200 million from prominent investors. BenchSci collaborates with 9 of the top 10 pharmaceutical companies, over 4,500 academic institutions, and more than 50,000 scientists.

Before founding BenchSci, Belenzon achieved his commerce and law degrees and sold his first startup. He then immigrated to Canada to pursue an MBA at the Rotman School of Management at the University of Toronto. During his time at Rotman, he participated in the Creative Destruction Lab, where he connected with three fellow PhD students who shared his vision for leveraging AI to enhance drug discovery. As CEO, Belenzon is dedicated to making a positive impact on the world through the advancement of life-saving research.